# Phase 1 leukemia trials recruiting: 246 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 246 trials in phase 1 for leukemia that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 leukemia trials: 246 rows for $12.30, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/leukemia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 246
- Recruiting or not yet: 246
- Read on: November 19, 2026

## Trials

The 25 newest of 246, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2026 | NCT07929740 | Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS | Kura Oncology, Inc. | Phase 1 | Not yet recruiting | Myelodysplastic Syndrome (MDS)/AML, Myeloid Leukemia, Acute | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929740) |
| November 6, 2026 | NCT07923071 | A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment | Syndax Pharmaceuticals | Phase 1 | Not yet recruiting | Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923071) |
| November 2, 2026 | NCT07909733 | Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT | University of Wisconsin, Madison | Phase 1 | Not yet recruiting | High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation, Acute Myeloid Leukemia (AML), Chronic Myeloid... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909733) |
| October 29, 2026 | NCT07905027 | A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML | Seattle Children's Hospital | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia, Acute Myeloid Leukaemia Recurrent, Acute Myeloid Leukaemia Refractory | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905027) |
| October 27, 2026 | NCT07897136 | CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897136) |
| October 23, 2026 | NCT07891468 | huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers | University of Pennsylvania | Phase 1 | Not yet recruiting | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Richter's Transformation | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891468) |
| September 25, 2026 | NCT07841002 | CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Relapsed/Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841002) |
| September 18, 2026 | NCT07828535 | Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia (AML) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828535) |
| September 10, 2026 | NCT07814339 | Hydrochloroquinine & Decitabine With Venetoclax in AML | Rutgers, The State University of New Jersey | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814339) |
| August 21, 2026 | NCT07780565 | Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome | M.D. Anderson Cancer Center | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780565) |
| August 11, 2026 | NCT07758218 | Allogeneic iNKT Cell Therapy (agenT-797) After SCT | University of Wisconsin, Madison | Phase 1 | Recruiting | Allogenic Stem Cell Transplantation, Myeloid Malignancies, Lymphoid Malignancies, Acute Myeloid Leukemia, Chronic... | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758218) |
| August 7, 2026 | NCT07751991 | A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML | Charm Therapeutics | Phase 1 | Recruiting | AML (Acute Myeloid Leukemia) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751991) |
| July 30, 2026 | NCT07737769 | Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or... | University of Michigan Rogel Cancer Center | Phase 1 | Recruiting | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07737769) |
| July 23, 2026 | NCT07723703 | Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML | Amphista Therapeutics Ltd | Phase 1 | Recruiting | Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723703) |
| July 23, 2026 | NCT07722767 | A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients | Cullinan Therapeutics Inc. | Phase 1 | Not yet recruiting | AML (Acute Myeloid Leukemia) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722767) |
| July 9, 2026 | NCT07692529 | A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Recruiting | Large Granular Lymphocyte Leukemia, T-LGL Leukemia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07692529) |
| July 1, 2026 | NCT07679919 | BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies | Luminary Therapeutics | Phase 1 | Not yet recruiting | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Multiple Myeloma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679919) |
| June 25, 2026 | NCT07668557 | Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | iCell Gene Therapeutics | Phase 1 | Recruiting | Acute Myeloid Leukemia (AML) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668557) |
| June 22, 2026 | NCT07661095 | A Study of CRD3874-SI in People With Leukemia | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Acute Myeloid Leukemia, AML, Refractory Acute Myeloid Leukemia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07661095) |
| June 16, 2026 | NCT07651878 | Vididencel in CML-CP Patients With MRD | Mendus | Phase 1 | Recruiting | CML (Chronic Myelogenous Leukemia) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07651878) |
| June 12, 2026 | NCT07645469 | FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia | Fred Hutchinson Cancer Center | Phase 1 | Recruiting | Acute Myeloid Leukemia | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07645469) |
| June 1, 2026 | NCT07617363 | ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS | Washington University School of Medicine | Phase 1 | Recruiting | Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617363) |
| May 29, 2026 | NCT07616089 | Phase I Study of FXS0683 in the Treatment of Blood Tumors | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Recruiting | B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616089) |
| May 29, 2026 | NCT07614022 | A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute... | Wake Forest University Health Sciences | Phase 1 | Recruiting | Philadelphia Positive Acute Lymphoblastic Leukemia | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614022) |
| May 14, 2026 | NCT07586618 | First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic... | Allterum Therapeutics, Inc | Phase 1 | Recruiting | Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586618) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 12 |
| City of Hope Medical Center | 11 |
| Institute of Hematology & Blood Diseases Hospital, China | 7 |
| National Cancer Institute (NCI) | 6 |
| Dana-Farber Cancer Institute | 6 |
| Mayo Clinic | 5 |
| Stanford University | 5 |
| Memorial Sloan Kettering Cancer Center | 4 |
| OHSU Knight Cancer Institute | 4 |
| St. Jude Children's Research Hospital | 3 |
| Kura Oncology, Inc. | 3 |
| Montefiore Medical Center | 3 |
| Fred Hutchinson Cancer Center | 3 |
| Baylor College of Medicine | 3 |
| University of Wisconsin, Madison | 3 |
| Seattle Children's Hospital | 2 |
| Nurix Therapeutics, Inc. | 2 |
| Shenzhen Geno-Immune Medical Institute | 2 |
| Medical College of Wisconsin | 2 |
| Lomond Therapeutics Holdings, Inc. | 2 |
| The First Affiliated Hospital of Xiamen University | 2 |
| [Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.](https://specstream.ai/data/clinical-trials/company/shanghai-fosun-pharmaceutical-industrial-development-co-ltd) | 2 |
| University of Pennsylvania | 2 |
| First Affiliated Hospital of Zhejiang University | 2 |
| Massachusetts General Hospital | 2 |

## By country

| Country | Trials |
| --- | --- |
| United States | 167 |
| China | 46 |
| Australia | 12 |
| Spain | 11 |
| France | 9 |
| United Kingdom | 9 |
| Italy | 7 |
| Poland | 7 |
| Germany | 5 |
| Canada | 5 |
| South Korea | 4 |
| Netherlands | 3 |
| Belgium | 3 |
| Romania | 3 |
| Denmark | 2 |
| Japan | 2 |
| Taiwan | 2 |
| Switzerland | 2 |
| Moldova | 2 |
| Ukraine | 2 |
| Armenia | 2 |
| Bulgaria | 2 |
| Lithuania | 2 |
| Slovakia | 2 |
| Russia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Drive thru bars in the United States](https://specstream.ai/data/businesses/drive-thru-bars/united-states)
- [Shutters companies in the United States](https://specstream.ai/data/businesses/shutters-companies/united-states)
- [Farm equipment suppliers in the United States](https://specstream.ai/data/businesses/farm-equipment-suppliers/united-states)
- [Tex-Mex restaurants in the United States](https://specstream.ai/data/businesses/tex-mex-restaurants/united-states)
- [Graphic design firms in the United States](https://specstream.ai/data/businesses/graphic-design-firms/united-states)
- [Water heater installers in the United States](https://specstream.ai/data/businesses/water-heater-installers/united-states)
